Global & US Botulism Illness Market by Drug types (antibiotics, antitoxins, others (trivalent, heptavalent) and by Applications (hospitals, pharmacies, clinics, others) Forecast: 2022-2030

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Technique

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL & US BOTULISM ILLNESS MARKET , BY TYPE

6.1. Overview

6.2. Antibiotics

6.3. Antitoxins

6.4. Others

7. GLOBAL & US BOTULISM ILLNESS MARKET , BY APPLICATION

7.1. Overview

7.2. Hospitals

7.3. Pharmacies

7.4. Clinics

8. GLOBAL & US BOTULISM ILLNESS MARKET , BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPANY LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global & US Botulism Illness Market

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global & US Botulism Illness Market

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2022

9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES

10.1. Revance Therapeutics Inc.

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Product Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. XOMA Corporation

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Product Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Molecular Targeting Technologies.

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Product Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. AlphaVax

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Product Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Eisai Corporation of North America, Inc.

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Product Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Microbiotix

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Product Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Abbvie, Inc

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Product Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. Bausch Health Companies Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Product Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Merz Pharma

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Product Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Supernus Pharmaceuticals, Inc.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Product Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL & US BOTULISM ILLNESS MARKET , SYNOPSIS, 2019–2032

TABLE 2 GLOBAL & US BOTULISM ILLNESS MARKET , ESTIMATES & FORECAST, 2019–2032 (USD MILLION)

TABLE 3 GLOBAL & US BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 4 GLOBAL & US BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 5 GLOBAL & US BOTULISM ILLNESS MARKET , BY REGION, 2019–2032 (USD MILLION)

TABLE 6 NORTH AMERICA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 7 NORTH AMERICA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 8 NORTH AMERICA: BOTULISM ILLNESS MARKET , BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 9 US: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 10 US: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 11 CANADA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 12 CANADA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 13 EUROPE: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 14 EUROPE: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 15 EUROPE: BOTULISM ILLNESS MARKET , BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 16 GERMANY: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 17 GERMANY: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 18 FRANCE: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 19 FRANCE: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 20 ITALY: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 21 ITALY: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 22 SPAIN: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 23 SPAIN: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 24 UK: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 25 UK: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 26 REST OF EUROPE: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 27 REST OF EUROPE: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 28 ASIA-PACIFIC: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 29 ASIA-PACIFIC: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 30 ASIA-PACIFIC: BOTULISM ILLNESS MARKET , BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 31 JAPAN: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 32 JAPAN: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 33 CHINA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 34 CHINA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 35 INDIA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 36 INDIA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 37 AUSTRALIA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 38 AUSTRALIA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 39 SOUTH KOREA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 40 SOUTH KOREA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 41 REST OF ASIA-PACIFIC: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 42 REST OF ASIA-PACIFIC: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 43 REST OF THE WORLD: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 44 REST OF THE WORLD: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 45 REST OF THE WORLD: BOTULISM ILLNESS MARKET , BY COUNTRY, 2019–2032 (USD MILLION)

TABLE 46 MIDDLE EAST: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 47 MIDDLE EAST: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 48 AFRICA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 49 AFRICA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

TABLE 50 LATIN AMERICA: BOTULISM ILLNESS MARKET , BY TYPE, 2019–2032 (USD MILLION)

TABLE 51 LATIN AMERICA: BOTULISM ILLNESS MARKET , BY APPLICATION, 2019–2032 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL & US BOTULISM ILLNESS MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL & US BOTULISM ILLNESS MARKET

FIGURE 4 GLOBAL & US BOTULISM ILLNESS MARKET , SHARE (%), BY TYPE, 2022

FIGURE 5 GLOBAL & US BOTULISM ILLNESS MARKET , SHARE (%), BY APPLICATION, 2022

FIGURE 6 GLOBAL & US BOTULISM ILLNESS MARKET , SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: BOTULISM ILLNESS MARKET , SHARE (%), BY COUNTRY, 2022

FIGURE 8 EUROPE: BOTULISM ILLNESS MARKET , SHARE (%), BY COUNTRY, 2022

FIGURE 9 ASIA-PACIFIC: BOTULISM ILLNESS MARKET , SHARE (%), BY COUNTRY, 2022

FIGURE 10 REST OF THE WORLD: BOTULISM ILLNESS MARKET , SHARE (%), BY COUNTRY, 2022

FIGURE 11 GLOBAL & US BOTULISM ILLNESS MARKET : COMPANY SHARE ANALYSIS (%), 2022

FIGURE 12 REVANCE THERAPEUTICS INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 REVANCE THERAPEUTICS INC: SWOT ANALYSIS

FIGURE 14 XOMA CORPORATION.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 XOMA CORPORATION.: SWOT ANALYSIS

FIGURE 16 MOLECULAR TARGETING TECHNOLOGIES : FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 MOLECULAR TARGETING TECHNOLOGIES : SWOT ANALYSIS

FIGURE 18 ALPHAVAX: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 ALPHAVAX: SWOT ANALYSIS

FIGURE 20 EISAI CORPORATION OF NORTH AMERICA, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 EISAI CORPORATION OF NORTH AMERICA, INC: SWOT ANALYSIS

FIGURE 22 MICROBIOTIX: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 MICROBIOTIX: SWOT ANALYSIS

FIGURE 24 ABBVIE, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 ABBVIE, INC: SWOT ANALYSIS

FIGURE 26 BAUSCH HEALTH COMPANIES INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 BAUSCH HEALTH COMPANIES INC: SWOT ANALYSIS

FIGURE 28 MERZ PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 MERZ PHARMA: SWOT ANALYSIS

FIGURE 30 SUPERNUS PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 SUPERNUS PHARMACEUTICALS, INC. SWOT ANALYSIS